查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1798030

2032 年自体免疫皮肤病治疗市场预测：按疾病类型、治疗类型、给药途径、最终用户和地区进行的全球分析

Autoimmune Skin Diseases Treatment Market Forecasts to 2032 - Global Analysis By Disease Type, Therapy Type, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球自体免疫皮肤病治疗市场预计在 2025 年达到 100.5 亿美元，到 2032 年将达到 257.7 亿美元，预测期内的复合年增长率为 14.4%。

「皮肤自体免疫疾病治疗」指用于治疗因免疫系统无意中攻击健康皮肤细胞而引起的皮肤疾病的医疗程序。干癣、白斑、红斑性狼疮、硬皮症、天疱疮和疱疹性皮肤炎都是这类疾病。治疗的主要目标是尽量减少皮肤损伤、减轻发炎、抑制异常免疫反应、缓解症状并避免病情復发。常见的治疗方法方法包括全身性和局部使用皮质类固醇、免疫抑制剂、生技药品、照光治疗和支持性护肤。改善生活品质、减少併发症和减缓病情进展都依赖早期诊断和针对每位患者的个人化治疗策略。

自体免疫皮肤病盛行率不断上升

筛检的提高和认知度的提升，使得白斑症、狼疮和牛皮癣等疾病的诊断率不断上升。不断扩大的患者群体促使医疗保健专业人员采用标靶治疗、免疫调节剂和先进的生技药品。为了满足这些患者尚未满足的需求，药厂正在​​加大研发投入。此外，有利的医疗法规和皮肤病治疗可近性的改善，也推动了治疗的采用率不断提高。自体免疫皮肤病的盛行率不断上升，推动了市场的稳定扩张。

生技药品和先进疗法成本高昂

许多患者无力承担这些药物，限制了药物的可近性和依从性。高昂的费用也给保险公司和医疗保健系统带来压力，导致覆盖范围有限，报销困难。患者可能会选择疗效较差的治疗方案。这些经济障碍阻碍了最先进治疗的广泛应用，并限制了市场成长。

医疗支出和诊断成长

增加津贴，鼓励使用尖端生技药品和针对性治疗方法，将改善患者的治疗效果。诊断能力的进步将使疾病分类更加准确，并实现更早的发现。透过早期准确的诊断进行及时干预，将减缓疾病进展和併发症。随着医疗基础设施的发展，都市区将有可能提高治疗的可近性。这些因素将共同增加对自体免疫皮肤病治疗的需求，从而推动市场成长。

安全性问题和副作用

许多治疗方法都存在严重副作用的风险，例如感染疾病和器官损伤。这些健康危害可能导致患者避免或停止治疗。此外，如果某些药物的安全性较差，医生可能不愿意推荐。这导致患者依从性和市场接受度较低。因此，对风险的担忧阻碍了有益药物的采用。

COVID-19的影响

新冠疫情对自体免疫皮肤病治疗市场造成了重大衝击，扰乱了供应链，推迟了临床试验，并限制了患者就医。医疗资源的关闭和重新分配推迟了诊断和治疗时间，影响了患者的治疗效果。远端医疗的普及加速，使得远距会诊和药物配製管理成为可能。製药公司在生产和分销方面面临挑战，但同时，他们也更专注于开发先进的治疗方法。疫情后的復苏将由选择性治疗的恢復、医疗保健可近性的改善以及对自体免疫皮肤病管理意识的提高所推动。

生技药品领域预计将成为预测期内最大的细分市场

生技药品领域预计将在预测期内占据最大的市场占有率，这得益于其提供针对潜在免疫功能障碍的标靶治疗。与传统药物相比，这些疗法疗效较佳、缓解期更长，刺激了患者需求。生技药品及其给药方式的进步提高了安全性和便利性，从而提高了采用率。用于治疗牛皮癣和异位性皮肤炎等疾病的新型生技药品的核准不断增加，扩大了治疗组合。医疗保健提供者和患者意识的不断增强，进一步推动了生技药品市场的成长。

预计预测期内居家照护领域将以最高的复合年增长率成长。

预计居家照护领域将在预测期内实现最高成长率，因为患者可以在家中便捷地接受治疗和监测，从而减少频繁就医的需求。自我给药选项和医疗保健提供者的远距指导也有助于提高治疗依从性。行动装置和远端医疗的进步使居家照护更加可行。整体而言，居家照护可以改善患者的治疗效果，同时降低医疗成本，进而推动市场成长。

比最大的地区

预计北美地区将在预测期内占据最大的市场占有率，这得益于其高发病率、完善的医疗基础设施和雄厚的研发资金。先进药物，尤其是生技药品和JAK抑制剂，以及优惠的报销政策，正在支持新治疗方法的快速应用。监管机构正在加速药品核准，并鼓励生物相似药的上市。尖端诊断和精准医疗技术（例如基于人工智慧的成像和多重检测）的使用日益增多，以及生物技术公司和学术机构之间的战略合作伙伴关係，正在推动牛皮癣、湿疹和狼疮等疾病治疗方法的持续创新。

复合年增长率最高的地区

预计亚太地区在预测期内的复合年增长率最高，这主要得益于人口老化、都市化和生活方式的改变导致自体免疫疾病盛行率上升。医疗基础设施投资、公共保险覆盖范围的扩大以及学名药的生产将提高治疗的可及性。新兴技术包括人工智慧远端皮肤病学、移动诊断、高光谱影像以及正在开发的奈米结构局部治疗。全球创新趋势强调经济高效的在地化解决方案，并透过与全球製药公司的合作，支援根据本地需求和医疗保健差异客製化诊断和精准医疗的可扩展部署。

免费客製化服务

订阅此报告的客户可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场参与企业进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 透过产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球自体免疫皮肤病治疗市场（依疾病类型）

  • 介绍
  • 银屑病
  • 异位性皮肤炎
  • 白斑
  • 寻常型天疱疮
  • 红斑狼疮
  • 其他的

6. 全球自体免疫皮肤病治疗市场（依治疗类型）

  • 介绍
  • 生技药品
  • 皮质类固醇
  • 免疫抑制剂
  • 小分子药物
  • 其他的

7. 全球自体免疫皮肤病治疗市场（依给药途径）

  • 介绍
  • 口服
  • 注射
  • 局部的

8. 全球自体免疫皮肤病治疗市场（依最终用户）

  • 介绍
  • 医院
  • 专科诊所
  • 居家照护
  • 其他的

9. 全球自体免疫皮肤病治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要发展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Biogen Inc.
  • Sanofi SA
  • UCB SA
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Roche Holding AG
  • Horizon Therapeutics plc
  • Incyte Corporation
Product Code: SMRC30400

According to Stratistics MRC, the Global Autoimmune Skin Diseases Treatment Market is accounted for $10.05 billion in 2025 and is expected to reach $25.77 billion by 2032 growing at a CAGR of 14.4% during the forecast period. Autoimmune Conditions of the Skin the term "treatment" describes the medical procedures used to treat skin conditions brought on by the immune system inadvertently targeting healthy skin cells. Psoriasis, vitiligo, lupus erythematosus, scleroderma, pemphigus, and dermatitis herpetiformis are some of these ailments. The main goals of treatment are to minimise skin damage, reduce inflammation, inhibit aberrant immune responses, relieve symptoms, and avoid flare-ups. Systemic and topical corticosteroids, immune-suppressants, biologic treatments, phototherapy, and supportive skincare are common methods. Improving quality of life, decreasing complications, and delaying the progression of disease all depend on early diagnosis and individualized treatment strategies.

Market Dynamics:

Driver:

Rising prevalence of autoimmune skin conditions

Improved screening and more awareness have led to a rise in the diagnosis of conditions like vitiligo, lupus, and psoriasis. Healthcare professionals are adopting targeted treatments, immune-modulators, and sophisticated biologics as a result of this expanding patient base. To meet these patients' unmet requirements, pharmaceutical companies are increasing their research and development expenditures. Treatment adoption rates are also increased by favourable healthcare regulations and improved access to dermatological care. All things considered, the growing prevalence of autoimmune skin conditions drives steady market expansion.

Restraint:

High cost of biologic and advanced therapies

The inability of many patients to pay for these medicines restricts their access and adherence. High costs also put a strain on insurance companies and healthcare systems. This results in limited coverage and difficulties with reimbursement. Patients might choose less effective options as a result. These monetary obstacles hinder the uptake of cutting-edge treatments and limit market growth.

Opportunity:

Growth in healthcare expenditure and diagnostics

Patient outcomes are improved by increased funding, which encourages the use of cutting-edge biologics and focused treatments. More precise disease classification and earlier detection are made possible by advancements in diagnostic capabilities. Timely intervention by early and accurate diagnosis slows the progression and complications of disease. Increased access to treatment in both urban and rural areas is made possible by growing healthcare infrastructure. These elements work together to increase demand and grow the market for treatments for autoimmune skin conditions.

Threat:

Safety concerns and adverse effects

The danger of serious side effects, like infections or organ damage, is present with many treatments. These health hazards may cause patients to avoid or stop receiving therapy. Additionally, doctors can be reluctant to recommend particular medications if their safety profiles are weak. Patient compliance and market acceptance are lowered as a result. Therefore, the adoption of beneficial medicines is slowed by the fear of danger.

Covid-19 Impact:

The Covid-19 pandemic significantly influenced the Autoimmune Skin Diseases Treatment Market by disrupting supply chains, delaying clinical trials, and limiting patient access to healthcare facilities. Lockdowns and healthcare resource reallocation led to postponed diagnoses and treatment schedules, impacting patient outcomes. Telemedicine adoption accelerated, enabling remote consultations and prescription management. Pharmaceutical companies faced challenges in production and distribution but also saw increased focus on developing advanced therapies. Post-pandemic recovery is driven by resumed elective treatments, improved healthcare accessibility, and growing awareness of autoimmune skin disease management.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period by offering targeted therapies that address the underlying immune system dysfunction. These treatments provide higher efficacy and longer remission periods compared to conventional drugs, boosting patient demand. Advancements in biologic formulations and delivery methods enhance safety and convenience, increasing adoption rates. Growing approvals of novel biologics for conditions like psoriasis and atopic dermatitis expand the treatment portfolio. Rising awareness among healthcare providers and patients further accelerates market growth for biologics.

The homecare settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the homecare settings segment is predicted to witness the highest growth rate by offering patients convenient access to therapies and monitoring in their own homes, reducing the need for frequent hospital visits. It supports better treatment adherence through self-administration options and remote guidance from healthcare providers. Advancements in portable devices and telemedicine enhance the feasibility of home-based care. Overall, homecare settings improve patient outcomes while lowering healthcare costs, driving market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share is driven by high disease prevalence, well developed healthcare infrastructure, and robust research funding. Advanced pharmaceuticals particularly biologics and JAK inhibitors plus favourable reimbursement policies support rapid adoption of novel therapies. Regulatory agencies facilitate accelerated drug approvals and bio similar entry. Cutting edge diagnostic and precision medicine technologies, including AI assisted imaging and multiplex assays, are increasingly used, with strategic collaborations between biotech firms and academic institutions powering continuous innovation in therapies for conditions such as psoriasis, eczema and lupus.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR is fuelled by rising autoimmune disease incidence tied to aging populations, urbanization and evolving lifestyles. Investments in healthcare infrastructure, expansion of public insurance coverage and generics production bolster treatment access. Emerging technologies include AI enabled teledermatology, mobile diagnostics, and hyper spectral imaging and nanostructure topical therapeutics under development. Regional innovation trends emphasize cost-effective, localized solutions-often in collaboration with global pharma supporting scalable deployment of diagnostics and precision therapies tailored to regional needs and healthcare disparities.

Key players in the market

Some of the key players in Autoimmune Skin Diseases Treatment Market include AbbVie Inc., Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Bristol Myers Squibb Company, Biogen Inc., Sanofi S.A., UCB S.A., GlaxoSmithKline plc, Regeneron Pharmaceuticals, Inc., AstraZeneca plc, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Horizon Therapeutics plc and Incyte Corporation.

Key Developments:

In April 2025, Amgen announced a $900 million expansion of its New Albany, Ohio biomanufacturing facility. The investment aims to boost production capacity for both pipeline and commercial biologics, potentially supporting treatments in autoimmune dermatology. This expansion strengthens Amgen's manufacturing network to meet growing global demand for innovative therapies.

In January 2025, AbbVie completed its ~$200 million acquisition of Nimble Therapeutics, gaining its lead oral peptide IL 23 receptor inhibitor for psoriasis and inflammatory bowel disease, along with Nimble's proprietary peptide drug discovery platform to advance targeted autoimmune disease therapies.

In June 2023, Eli Lilly agreed to acquire Dice Therapeutics for $2.4 billion in cash (approximately $48 per share). The deal focuses on Dice's innovative oral IL 17 inhibitors, notably DC 806 in phase II psoriasis trials, along with other pipeline assets aimed at advancing treatments for autoimmune and inflammatory skin diseases.

Disease Types Covered:

  • Psoriasis
  • Atopic Dermatitis
  • Vitiligo
  • Pemphigus Vulgaris
  • Lupus Erythematosus
  • Other Disease Types

Therapy Types Covered:

  • Biologics
  • Corticosteroids
  • Immunosuppressants
  • Small Molecule Drugs
  • Other Therapy Types

Route of Administrations Covered:

  • Oral
  • Injectable
  • Topical

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoimmune Skin Diseases Treatment Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Psoriasis
  • 5.3 Atopic Dermatitis
  • 5.4 Vitiligo
  • 5.5 Pemphigus Vulgaris
  • 5.6 Lupus Erythematosus
  • 5.7 Other Disease Types

6 Global Autoimmune Skin Diseases Treatment Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Biologics
  • 6.3 Corticosteroids
  • 6.4 Immunosuppressants
  • 6.5 Small Molecule Drugs
  • 6.6 Other Therapy Types

7 Global Autoimmune Skin Diseases Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Topical

8 Global Autoimmune Skin Diseases Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Specialty Clinics
  • 8.4 Homecare Settings
  • 8.5 Other End Users

9 Global Autoimmune Skin Diseases Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AbbVie Inc.
  • 11.2 Amgen Inc.
  • 11.3 Eli Lilly and Company
  • 11.4 Johnson & Johnson Services, Inc.
  • 11.5 Novartis AG
  • 11.6 Pfizer Inc.
  • 11.7 Bristol Myers Squibb Company
  • 11.8 Biogen Inc.
  • 11.9 Sanofi S.A.
  • 11.10 UCB S.A.
  • 11.11 GlaxoSmithKline plc
  • 11.12 Regeneron Pharmaceuticals, Inc.
  • 11.13 AstraZeneca plc
  • 11.14 Merck & Co., Inc.
  • 11.15 Takeda Pharmaceutical Company Limited
  • 11.16 Roche Holding AG
  • 11.17 Horizon Therapeutics plc
  • 11.18 Incyte Corporation

List of Tables

  • Table 1 Global Autoimmune Skin Diseases Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 3 Global Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 4 Global Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 5 Global Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 6 Global Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 7 Global Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 8 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 9 Global Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 10 Global Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 11 Global Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 12 Global Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 13 Global Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 14 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 15 Global Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 16 Global Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 17 Global Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 18 Global Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 19 Global Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 20 Global Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 21 Global Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 22 Global Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 23 Global Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 24 North America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 25 North America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 26 North America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 27 North America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 28 North America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 29 North America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 30 North America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 31 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 32 North America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 33 North America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 34 North America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 35 North America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 36 North America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 37 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 38 North America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 39 North America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 40 North America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 41 North America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 42 North America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 43 North America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 44 North America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 45 North America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 46 North America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 47 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 48 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 49 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 50 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 51 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 52 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 53 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 54 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 55 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 56 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 57 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 58 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 59 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 60 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 61 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 62 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 63 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 64 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 65 Europe Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 66 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 67 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 68 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 69 Europe Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 70 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 71 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 72 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 73 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 74 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 75 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 76 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 77 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 78 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 79 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 80 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 81 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 82 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 83 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 84 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 85 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 86 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 87 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 88 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 89 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 90 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 91 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 92 Asia Pacific Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 93 South America Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 94 South America Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 95 South America Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 96 South America Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 97 South America Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 98 South America Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 99 South America Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 100 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 101 South America Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 102 South America Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 103 South America Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 104 South America Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 105 South America Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 106 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 107 South America Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 108 South America Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 109 South America Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 110 South America Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 111 South America Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 112 South America Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 113 South America Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 114 South America Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 115 South America Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 116 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Country (2024-2032) ($MN)
  • Table 117 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 118 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Psoriasis (2024-2032) ($MN)
  • Table 119 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Atopic Dermatitis (2024-2032) ($MN)
  • Table 120 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Vitiligo (2024-2032) ($MN)
  • Table 121 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Pemphigus Vulgaris (2024-2032) ($MN)
  • Table 122 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Lupus Erythematosus (2024-2032) ($MN)
  • Table 123 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 124 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 125 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 126 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 127 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 128 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Small Molecule Drugs (2024-2032) ($MN)
  • Table 129 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other Therapy Types (2024-2032) ($MN)
  • Table 130 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 131 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 132 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 133 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 134 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 135 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 136 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 137 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 138 Middle East & Africa Autoimmune Skin Diseases Treatment Market Outlook, By Other End Users (2024-2032) ($MN)